VEGFA and pancreatic neuroendocrine tumor: Moreover, it has been proved that concurrent Ang-2 and VEGF blockade confers significant therapeutic benefits compared with the blockade of single agent in tumor models concerning metastatic breast cancer, pancreatic neuroendocrine tumor, and melanoma [35,45].